Internal Medicine (Digestive Diseases), Yale University School of Medicine, New Haven, Connecticut, USA.
Department of Pediatrics (General Pediatrics), Yale University School of Medicine, New Haven, Connecticut, USA.
J Med Food. 2020 May;23(5):560-563. doi: 10.1089/jmf.2019.0116. Epub 2019 Nov 22.
Soy-based beverages are well recognized for their rich nutritional contents and positive health benefits. However, there is little information regarding the composition of various commercially available soy-based beverages and uncertainty among patients regarding the utility of fermented soy products. Current study evaluates the health benefits of QCAN Plus-an easily available fermented soy drink. This study was performed in lean ( = 10) and obese ( = 10) subjects. The subjects were observed during pre-soy (weeks -2, -1, and 0), on-soy (weeks 1, 2, 3, and 4), and post-soy (weeks 6, 8, 10, and 12) periods. The serum samples during these visits were subjected to lipid profile analysis and multiplex assay for cytokines. The results revealed that total cholesterol and low-density lipoprotein (LDL) cholesterol levels were significantly reduced in both lean and obese individuals during on-soy ( ≤ .05). Furthermore, cytokines such as platelet-derived growth factor (PDGF) AA and AB/BB were significantly lowered on-soy compared with pre-soy ( ≤ .05) in lean subjects and PDGF AA, IL-1RA, and GMCSF were significantly reduced on-soy ( ≤ .05) in obese subjects. In addition, a qualitative and quantitative analysis of the Q-CAN Plus by a third-party laboratory confirmed its chemical and microbial safety. Our preliminary study on Q-CAN Plus ensures its safety for consumption and highlights its hypolipidemic and suppressive effect on certain cytokines. These observations and relevant studies in future might guide clinicians in future to consider Q-CAN Plus as a therapeutic nutritional supplement.
以大豆为基础的饮料因其丰富的营养成分和对健康的积极益处而广为人知。然而，关于各种市售的以大豆为基础的饮料的成分，以及患者对发酵大豆产品的实用性的不确定性，信息很少。目前的研究评估了 QCAN Plus-一种易于获得的发酵大豆饮料的健康益处。这项研究在瘦（n = 10）和肥胖（n = 10）受试者中进行。在服用大豆之前（第-2、-1 和 0 周）、服用大豆期间（第 1、2、3 和 4 周）和服用大豆之后（第 6、8、10 和 12 周）观察这些受试者。在这些访问期间采集血清样本，进行脂质谱分析和细胞因子的多重分析。结果表明，在服用大豆期间，瘦人和肥胖者的总胆固醇和低密度脂蛋白（LDL）胆固醇水平均显著降低（≤.05）。此外，与服用大豆之前相比（≤.05），瘦受试者的血小板衍生生长因子（PDGF）AA 和 AB/BB 以及肥胖受试者的 PDGF AA、IL-1RA 和 GMCSF 等细胞因子在服用大豆期间显著降低。此外，第三方实验室对 Q-CAN Plus 的定性和定量分析证实了其化学和微生物安全性。我们对 Q-CAN Plus 的初步研究确保了其食用安全性，并强调了其对某些细胞因子的降血脂和抑制作用。这些观察结果和未来的相关研究可能会指导临床医生在未来将 Q-CAN Plus 视为一种治疗性营养补充剂。
